Safety and immunogenicity of palivizumab (Synagis) administered for two seasons.

Author(s): Null D Jr, Pollara B, Dennehy PH, Steichen J, Sanchez PJ, Givner LB, Carlin D, Landry B, Top FH Jr, Connor E

Affiliation(s): Primary Children's Medical Center, Salt Lake City, UT, USA.

Publication date & source: 2005-11, Pediatr Infect Dis J., 24(11):1021-3.

Publication type: Multicenter Study; Randomized Controlled Trial

To evaluate the safety and immunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.